The pharmaceutical lactose market is projected to be valued at USD 249.6 million in 2025 and is expected to reach USD 442.9 million by 2035, expanding at a CAGR of 5.9% over the forecast period.The industry has been following a steady curve of growth driven by the increase in its use as an excipient in the pharmaceutical sector.
The take-up of the industry often occurs in the form of tablets and capsules as a filler, binder, and stabilizer thanks to its favorable compressibility, solubility, and compatibility with active pharmaceutical ingredients (APIs). The industry sector has been aided through the rising demand for the manufacturing of drug-grade excipients that are of high quality.
The industry is mostly fueled by the growth of the pharmaceutical industry, especially those countries that are still emerging, where healthcare expenses are on the rise, and the increasing prevalence of drug production are pushing pharmaceutical-grade lactose demand up. The rise in the use of lactose excipients for DPIs (dry powder inhalers) in respiratory therapies is leading to an accompanying rise of lactose that assists in the effective delivery of pulmonary drugs.
Innovations in lactose manufacturing such as the introduction of cleaner purification and micronization methods have elevated the quality and performance of the products thereby making the industry the most sought-after excipients for drug manufacturers.
Also, the adherence to the international pharmaceutical standards such as USA Pharmacopeia (USP) and European Pharmacopoeia (Ph. Eur.) regulatory approvals are the reasons that product safety and consistency are being ensured.
Nevertheless, the lactose industry is grappling with difficulties like the rise in the number of people who have lactose intolerance and the shrinking demand for lactose-free excipients in drug formulations. Besides, the dairy production instability and raw material costs can have an effect on the supply and pricing of the industry causing headaches for the manufacturers. Moreover, compliance with the rigorous quality control measures and the regulatory formalities act as an obstacle for new entrants in the industry.
Regardless of these setbacks, industry growth pockets abound. The growing need for personalized medicine and specialized drug compositions is boosting the demand for custom-made excipients like the specific types of derivative lactose.
Also, the multiplication of research and development towards the creation of new drug delivery mechanism is expected to result in the introduction of new avenues for growth. The collaborations of pharmaceutical stocks with technology advances in drug formulation sectors are areas wherein the industry can benefit from sustainable development in the next few years.
Explore FMI!
Book a free demo
The industry is growing because of its extensive application as an excipient in solid and liquid dosage formulations. It is preferred because of its binding, filler, and carrier ability, and hence it is an essential ingredient in tablet, capsule, and dry powder inhaler (DPI) products.
The industry is especially valued in tablets and capsules due to its excellent flow ability and compressibility, ensuring smooth production. DPI business concentrates on lactose purity and particle size distribution for better drug delivery.
Parenteral products employ lactose as an osmotic agent with high solubility and purity standards. At the same time, nutraceuticals incorporate lactose as a stabilizer and carrier in nutritional supplements. As there is growing demand for lactose-free drugs and other excipients, producers are developing new lactose grades and microencapsulation methods to optimize performance in niche drug delivery systems.
The below table highlights a comparative analysis of the change in six-month CAGR in the base period (2024 to 2034) and forecast period (2025 to 2035) of the global industry. Representing missing adaptations of industry performance trends and account realization patterns over a decade, the analysis helps stakeholders realize critical changes. The first half of the year (H1) which runs from January to June, and the second half (H2) that runs from July to December.
| Particular | Value CAGR |
|---|---|
| H1 (2024 to 2034) | 5.7% |
| H2 (2024 to 2034) | 6% |
| H1 (2025 to 2035) | 5.8% |
| H2 (2025 to 2035) | 6.1% |
The industry is projected to grow 5.7% in H1 (2025 to 2035) and a higher 6.1% in H2 (2025 to 2035). This sector delivered a never-ending growth of 20 BPS in H1, and H2 followed with 40 BPS more, in Pharma applications demand reflection.
The industry increased steadily from 2020 to 2024 due to increasing demand for lactose as a binder and filler in tablet formulations. The industry was in demand due to its compressibility, stability, and active pharmaceutical ingredient (API) compatibility.
Generic drug production surged and pharmaceutical production increased in developing countries, boosting demand for pharmaceutical grade lactose. Anhydrous and spray-dried forms of lactose were sought after since they showed improved flow and binding properties, enhancing the efficiency of tablet production.
Industry stability was complicated by supply chain interruptions and fluctuations in raw material prices. Additionally, growing awareness about lactose intolerance and other alternative excipients limited wider use in certain formulations used in pharmacy.
During 2025 to 2035, the industry will expand further with the support of technological developments in lactose processing and increasing demand for oral solid dosage forms. Lactose co-processed excipients from lactose and combined with other functional excipients will promote tablet disintegration, solubility, and drug bioavailability.
Lactose technology using granulation technologies and direct compression methods will make lactose more effective in high-speed manufacturing lines. Additionally, increasing biopharmaceuticals and drug formulation complexity will drive high-end lactose derivatives of higher purity and consistency. Green manufacturing operations, such as the use of vegetable lactose alternatives, will keep up with environmental standards and keep pace with the growing need for green excipients.
Comparative Market Shift Analysis 2020 to 2024 vs. 2025 to 2035
| 2020 to 2024 | 2025 to 2035 |
|---|---|
| Use as a tablet binder and filler. | Co-processing lactose excipients enhances drug disintegration and bioavailability. |
| Spray-dried lactose and anhydrous lactose favored due to improved flow and binding. | Higher efficiency with the help of advanced granulation and direct compression technology. |
| Greater demand by generic drug companies. | Growing application in biopharmaceuticals and compound drugs. |
| Industry growth being restricted due to supply chain breakdown and price variation. | Sustainable and plant-based manufacturing options highly sought after. |
| Stepped introduction owing to the issue of lactose intolerance. | Increased purity and consistency fuel regulated industry demand. |
The industry is getting bigger with its extensive application as an excipient in drug formulations. Nevertheless, pharmaceutical-grade lactose being under strict regulatory requirements presents a compliance problem.
The companies have to guarantee their following the changes in safety and power standards, obtain the related certifications and be transparent to customers to preserve their trust and the industry acceptance. Production stumbling blocks, covering the lower milk supply, transport problems, and price cockeyed, have a direct effect on making the production steady and maintain costs.
Global warming, dairy sector regulations, and geopolitics disturbance of lactose trading largely create big uncertainties in the industry. For tackling those issues, firms are supposed to set up alternative supply channels and inject into local assembling.
Changing buyer preferences toward lactose-free and plant-based alternatives challenge traditional pharmaceutical lactose manufacturers. The enhancement of vegan-friendly drug formulations and growing concerns over lactose intolerance drive competition from synthetic and non-dairy excipients even higher.
Economic reverses, trade policies being changed, and the pharmaceutical industry shifting gears all impact industry growth. In order to ensure long-term success, companies should work on making their supply chain more efficient, enter new industries, and work with the drug manufacturers on the development of state-of-the-art pharmaceutical lactose solutions according to the industry needs.
| Countries | CAGR (2025 to 2035) |
|---|---|
| USA | 5.8% |
| Germany | 5.5% |
| China | 6% |
| India | 6.2% |
| Japan | 5.3% |
| UK | 5.4% |
| France | 5.2% |
| Italy | 5.1% |
| South Korea | 5.7% |
| Australia | 4.9% |
| New Zealand | 4.8% |
The USA is the leader in the worldwide industry, with a forecasted volume of USD 60.5 million in 2025 and a 5.8% CAGR from 2025 to 2035. This is because it has a highly developed pharmaceutical industry in which lactose is used extensively as an excipient in capsules and tablets. The USA is the lucky beneficiary of the finest research and development centers that produce novel and innovative lactose products.
Bodies such as the FDA aid in developing strict product standards, further stabilizing the industry. Groups such as Kerry Group and Foremost Farms USA act to increase industry size positively through high-purity lactose production.
With the growing need for solid oral dosage forms, lactose remains a popular excipient among manufacturers because of its higher compressibility and stability. The availability of various contract manufacturers and generic drug firms also increases the demand for lactose. Higher health consciousness has also assisted in the creation of derivatives of lactose, like lactose monohydrate, in fulfilling specialty formulations like pediatric and geriatric drugs.
Germany is a major lactose pharmacy industry in the European industry with a forecasted volume in 2025 of USD 45.2 million and 5.5% CAGR during the forecast period. German pharmaceuticals have experienced goodwill for precision and strict compliance with Good Manufacturing Practices (GMP) in delivering quality lactose utilized in formulation.
The availability of prominent pharma players such as Boehringer Ingelheim and Merck KGaA here supports formulation innovations with lactose to perpetuate. German research centers focus on new lactose derivatives to increase drug stability and bioavailability. In addition, the biopharmaceutical trend has also boosted the demand for lactose excipients in protein drug products. The German export-based pharmaceutical industry also supports the use of lactose as domestic drugs are being exported to every corner of the globe.
The industry of lactose in the Chinese pharma industry is expanding robustly, with an industry value of USD 38.7 million in 2025 and a 6.0% CAGR during 2025 to 2035. Demand has been driven by enhanced pharma production and healthcare spending in China. Greater activity by local drug makers like Sinopharm and Shanghai Pharma has played a crucial role in the surge in demand for quality excipients like lactose, which is an important component in tablet formulations.
Government efforts to boost pharma production in the country also align with lactose industry expansion. Since China is tightening its laws to international standards, the need for lactose is also on the increase. Moreover, increased research in lactose-based sustained-release products further pushes the industry.
The UK industry is anticipated to grow at a CAGR of 5.4% during 2025 to 2035. The robust pharmaceutical sector in the country, dominated by companies such as GlaxoSmithKline and AstraZeneca, is dependent on lactose as a filler for solid dosage forms. Lactose derivatives for precision medicine and targeted drug delivery are becoming increasingly popular with the increasing emphasis on precision medicine.
Regulatory bodies like the MHRA embrace rigorous control of quality, and thus, lactose of high purity is called for. On top of this, the UK's stable foundation of contract manufacturers likewise creates demand for lactose because overseas drugmakers buy excipients for their UK production facilities.
France's pharma lactose industry will grow at a 5.2% CAGR during 2025 to 2035. High-quality excipients, with the country's well-established pharma industry being the pioneer, are being tapped by pharmaceutical companies like Sanofi. Lactose-containing excipients are targeted by regional manufacturers in controlled-release drugs, improving drug efficacy and stability.
Increasing drug demand among the pediatric and geriatric populations has also encouraged lactose use in specialty pharmaceuticals. Moreover, France's research intensity is high, which facilitates innovation in lactose-based excipients with increased solubility to counter the growing demand for orally disintegrating tablets.
Italy's pharma lactose industry is predicted to grow at a CAGR of 5.1% during the forecast period. Italy's contract manufacturing and very generic pharma industry rely to a great extent on lactose as a bulk excipient. Lactose is applied by drug product makers like Chiesi Farmaceutici, further driving the industry.
Increased investment in more sophisticated drug delivery systems has also facilitated innovation in such lactose carriers. Lactose-free drug formulation for patients is also being developed, and this exhibits pharmaceutical lactose-free industry diversification.
South Korean lactose pharmaceutical industry will register a growth of 5.7% during the period between 2025 and 2035. South Korean pharmaceutical industry with the domination of industry giants such as Celltrion and Hanmi Pharmaceutical is making most of the usage of lactose in biosimilars. The strong biopharmaceutical sector of South Korea also contributes to lactose demand.
Since the government encourages domestic manufacture of drugs, excipients like lactose remain on the rise in terms of demand. Expansion in orally dispersible tablets, in which lactose forms a core constituent, is also increasingly becoming popular, thereby contributing to the growth of the industry.
The Australian industry will expand at 4.9% per year during the forecast period. Demand for excipients from renowned pharmaceutical players such as CSL Limited guarantees perpetual demand for lactose-based excipients. Increasing demand for natural and organic excipients in Australia has created opportunities for the development of lactose derivatives for clean-label drugs.
Increasing requirements for generic drugs, especially rural drugs, have also stimulated demand for lactose. The increase in the occurrence of chronic diseases has also created long-term demand for lactose in the form of extended-release formulations.
The New Zealand industry is expected to grow at a CAGR of 4.8% from 2025 to 2035. The New Zealand pharmaceutical industry, although smaller in scale compared to its peers, enjoys robust regulatory oversight along with quality production processes. Douglas Pharmaceuticals is one such firm that utilizes lactose in generics, thereby attaining high industry penetration.
New Zealand's focus on the utilization of natural drug ingredients has presented scientific investigation for alternatives to lactose. Lactose remains a top excipient as a result of its usefulness and stability. New Zealand's export of drugs to Asian-Pacific nations provides more demand for unpurified lactose.
| Segment | Value Share (2025) |
|---|---|
| Tablet Formulations (By Application) | 65% |
In the year 2025, the industry is also classified by application, which attributes the largest industry share of 65% to tablet formulation. An excipient with a major role in the manufacture of tablets is lactose as it acts as a binder, diluent, and filler whose use improves drug stability and compressibility.
α-Monohydrate Lactose is a widely used material specifically in the direct compression and wet granulation processes, making it a popular excipient in large-scale tablet manufacturing. Major suppliers for pharmaceutical excipients (DFE Pharma, Kerry Group, Meggle) have developed lactose-based excipients for faster tablet manufacturing.
Industry growth is attributed to the increasing demand for solid oral dosage forms, which represent almost half of the world's pharmaceutical drugs. The industry is segmented into Dry Powder Inhalers (DPIs): Accounting for 15%, the industry is driven by the rising cases of asthma, chronic obstructive pulmonary disease (COPD), and respiratory infections.
Due to its reduced hygroscopicity and stimulating aerosol matching, β-Lactose is an indispensable component of DPIs and guarantees drug delivery to the human lungs. Specialty lactose is produced by companies such as BASF and Merck KGaA for high-purity lactose for inhalation formulations for respiratory therapies.
The demand for lactose-based DPI excipients is likely to grow significantly with the WHO reporting more than 262 million COPD cases worldwide (2023). With the development of pharmaceutical formulations, the role of lactose remains of paramount importance in improving the bioavailability, stability and patient adherence of the drug and is expected to aid in creating sustain demand in both tablets and inhalation drug delivery systems.
Monohydrate Lactose: Leading the Pharmaceutical Lactose Product Segment
| Segment | Value Share (2025) |
|---|---|
| Monohydrate Lactose (By Product Type) | 58% |
The industry is segmented by type, with α-Monohydrate Lactose dominating with a 58% market share in 2025. The lactose variant is widely used as an excipient in solid oral dosage forms, including capsules and tablets, owing to its properties such as excellent flowability, compressibility, and stability.
In the case of α-Monohydrate Lactose, it is imported from well-known multinational players including DFE Pharma, Kerry Group, and Meggle; all of whom are proven to deliver consistent performance in any tablet formulation. Additionally, due to its high aqueous solubility, it can be used in both wet granulation and direct compression manufacturing processes, providing a more efficient method for large-scale drug production.
The highest volume of β-Lactose (16%) is utilized in dry powder inhalers (DPIs) and various particular pharmaceutical formulations. Due to its low hygroscopicity, it can improve aerosol dispersion and bioavailability in inhalation drug delivery.
Companies like BASF and Merck KGaA manufacture β-Lactose for respiratory medications, such as those used for asthma and chronic obstructive pulmonary disease (COPD). The global burden of respiratory disorders is increasing; worldwide, over 262 million people have COPD (WHO, 2023). This is increasing demand for bovine β-Lactose-based DPIs.
The industry is still expanding due to increasing investments in drug formulation technologies and a growing interest in high-performance excipients. Lactose has undergone modification by pharmaceutical manufacturers as excipients to provide stability, solubility, and compliance to patients, which is anticipated to provide the manufacturers with sustained demand owing to the aforementioned factors.
Pharmaceutical lactose is gaining traction due to its multiplex applications in excipients for tablets, filling capsules with powder, and dry powder inhalers. With the increased demand to produce pharmaceuticals coupled with the ever-increasing demands of high-purity lactose, along with ongoing advancements in the field of lactose-based delivery systems for drug formulations, the industry is expected to grow strongly in the future.
Leading players in the industry include Kerry Group, DFE Pharma, FrieslandCampina, Meggle, and Armor Pharma. They present many grades of lactose that are predominately available for their functions in pharmaceutical applications.
DFE Pharma has extended its portfolio to include lactose for continuous manufacturing, while Meggle is focused on spray-dried as well as micronized lactose for drug formulation efficiency improvements. The changing phases of the industry are mainly emerging through the enforcement of doc-level regulatory standards, advances in lactose-free alternatives, and rising applications in biopharmaceuticals.
Today, investments into advanced purification and eco-friendly production processes, as well as extensive collaborative strategic partnerships with drug manufacturers, to strengthen industry position are what can be seen in many pharmaceutical excipient firms.
Nevertheless, the strategic factors above concerning competition are supply chain optimization, compliance with global standards on pharmaceutical regulations, and innovations in lactose modification. Industry players are expanding R&D efforts, optimizing raw material sourcing, and leveraging digital solutions to enhance production efficiency and meet evolving pharmaceutical demands.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Kerry Group | 18-22% |
| DFE Pharma | 14-18% |
| Meggle Group | 10-14% |
| FrieslandCampina Domo | 8-12% |
| Armor Pharma | 6-10% |
| Other Players (Combined) | 25-35% |
| Company Name | Key Offerings & Market Focus |
|---|---|
| Kerry Group | Leading producer of pharmaceutical-grade lactose, focusing on custom excipient solutions and compliance with stringent regulatory standards. |
| DFE Pharma | Specializes in inhalation-grade and direct-compression lactose, used in orally administered drugs and DPIs. |
| Meggle Group | Offers high-purity lactose excipients for tablet formulations, powder blends, and capsule fillers. |
| FrieslandCampina Domo | Focuses on functional lactose solutions with an emphasis on precision manufacturing for enhanced bioavailability. |
| Armor Pharma | Develops pharmaceutical lactose excipients tailored for controlled drug release and high-performance drug formulations. |
Key Company Insights
Kerry Group (18-22%)
Industry leader in pharmaceutical lactose, providing high-purity excipients for direct compression and tablet forms.
DFE Pharma (14-18%)
Leading provider of inhalation-grade lactose, serving the increasing respiratory drug and DPI industry.
Meggle Group (10-14%)
Specialized in high-purity lactose for solid oral dosage forms, with competence in spray-dried and anhydrous lactose solutions.
FrieslandCampina Domo (8-12%)
Recognized for pharmaceutical-grade lactose with accurate excipient functionality, with support for customized drug formulation.
Armor Pharma (6-10%)
It specializes in customized lactose excipients, especially for controlled-release and enhanced bioavailability applications.
The global industry is projected to grow at a CAGR of 5.9% from 2025 to 2035.
The industry is anticipated to reach a valuation of approximately USD 442.9 million by 2035.
The tablet formulations segment is expected to witness the fastest growth due to its extensive use in drug manufacturing.
Increasing pharmaceutical production, rising demand for excipients, growing preference for high-purity lactose, and regulatory compliance requirements are key growth drivers.
Kerry Group, DFE Pharma, Meggle Group, FrieslandCampina Domo, Armor Pharma, Lactose India Limited, Molkerei Ammerland, Hilmar Ingredients, Innophos Holdings Inc., and DMV Fonterra Excipients are the key players in the industry.
By product type, the industry is segmented into monohydrate lactose, anhydrous lactose, spray-dried lactose, and specialty lactose.
By region, the industry is divided as North America, Latin America, Western Europe, Eastern Europe, South Asia & Pacific, East Asia, Central Asia, Balkan and Baltic Countries, Russia and Belarus, and The Middle East & Africa.
Yeast Extract Market Analysis by Type, Grade, Form, and End Use
USA Bubble Tea Market Analysis from 2025 to 2035
Food Testing Services Market Trends - Growth & Industry Forecast 2025 to 2035
USA Dehydrated Onions Market Insights – Size, Trends & Forecast 2025-2035
Latin America Dehydrated Onions Market Outlook – Demand, Share & Forecast 2025-2035
Europe Dehydrated Onions Market Analysis – Growth, Trends & Forecast 2025-2035
Pharmaceutical Lactose Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
